Literature DB >> 7209871

Effects of long term administration of ticlopidine on platelet function and hemostatic variables.

J Conard, C Lecrubier, P Y Scarabin, M H Horellou, M Samama, M G Bousser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7209871     DOI： 10.1016/0049-3848(80)90064-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  6 in total

1.  Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.

Authors:  M G Grimaldi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Authors:  G de Gaetano; V Bertelé
Journal:  Agents Actions       Date:  1984-01

Review 3.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

4.  Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

Authors:  A Aukland; R A Hurlow; A J George; J Stuart
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

5.  Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.

Authors:  C Lecrubier; J Conard; M H Horellou; M Samama
Journal:  Agents Actions       Date:  1983-02

6.  Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.

Authors:  T Yasuda; H K Gold; J T Fallon; R C Leinbach; J L Guerrero; L E Scudder; M Kanke; D Shealy; M J Ross; D Collen; B S Coller
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.